These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 16009823)

  • 21. Predisposition of infants with chronic lung disease to respiratory syncytial virus-induced respiratory failure: a vascular hypothesis.
    Carpenter TC; Stenmark KR
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S33-40. PubMed ID: 14730268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic lung disease of the very low birth weight infant--is it preventable?
    Ogawa Y
    Turk J Pediatr; 1998; 40(1):35-44. PubMed ID: 9673527
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Incidence of bronchopulmonary dysplasia in the course of the respiratory distress syndrome in premature infants].
    Tosch U; Becker-Gaab C; Dachs C
    Rofo; 1984 Aug; 141(2):167-71. PubMed ID: 6431538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Risk factors, frequency and severity of bronchopulmonary dysplasia (BPD) diagnosed according to the new disease definition in preterm neonates].
    Woynarowska M; Rutkowska M; Szamotulska K
    Med Wieku Rozwoj; 2008; 12(4 Pt 1):933-41. PubMed ID: 19471069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of preterm birth and bronchopulmonary dysplasia on the developing lung: long-term consequences for respiratory health.
    O'Reilly M; Sozo F; Harding R
    Clin Exp Pharmacol Physiol; 2013 Nov; 40(11):765-73. PubMed ID: 23414429
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal ventilatory strategies and surfactant to protect the preterm lungs.
    Ramanathan R
    Neonatology; 2008; 93(4):302-8. PubMed ID: 18525214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The surfactant system protects both fetus and newborn.
    Hallman M
    Neonatology; 2013; 103(4):320-6. PubMed ID: 23736009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bovine surfactant replacement therapy in neonates of less than 30 weeks' gestation: a randomized controlled trial of prophylaxis versus treatment.
    Dunn MS; Shennan AT; Zayack D; Possmayer F
    Pediatrics; 1991 Mar; 87(3):377-86. PubMed ID: 2000278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-frequency oscillatory ventilation: effects on lung function, mechanics, and airway cytokines in the immature baboon model for neonatal chronic lung disease.
    Yoder BA; Siler-Khodr T; Winter VT; Coalson JJ
    Am J Respir Crit Care Med; 2000 Nov; 162(5):1867-76. PubMed ID: 11069828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lung protective ventilatory strategies in very low birth weight infants.
    Ramanathan R; Sardesai S
    J Perinatol; 2008 May; 28 Suppl 1():S41-6. PubMed ID: 18446177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate.
    Engle WA;
    Pediatrics; 2008 Feb; 121(2):419-32. PubMed ID: 18245434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: a sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates.
    Groneck P; Götze-Speer B; Oppermann M; Eiffert H; Speer CP
    Pediatrics; 1994 May; 93(5):712-8. PubMed ID: 8165067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Surfactant treatment in premature infants with Respiratory Distress Syndrome in Curaçao.
    Verhagen AA; Keli SO; van der Meulen GN; Wiersma H; Arias M; Angelista IR; Muskiet FD
    West Indian Med J; 2001 Jun; 50(2):117-22. PubMed ID: 11677907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathology of new bronchopulmonary dysplasia.
    Coalson JJ
    Semin Neonatol; 2003 Feb; 8(1):73-81. PubMed ID: 12667832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Surfactant replacement therapy with a single postventilatory dose of a reconstituted bovine surfactant in preterm neonates with respiratory distress syndrome: final analysis of a multicenter, double-blind, randomized trial and comparison with similar trials. The Surfactant-TA Study Group.
    Fujiwara T; Konishi M; Chida S; Okuyama K; Ogawa Y; Takeuchi Y; Nishida H; Kito H; Fujimura M; Nakamura H
    Pediatrics; 1990 Nov; 86(5):753-64. PubMed ID: 2235230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polymorphisms of surfactant protein A genes and the risk of bronchopulmonary dysplasia in preterm infants.
    Weber B; Borkhardt A; Stoll-Becker S; Reiss I; Gortner L
    Turk J Pediatr; 2000; 42(3):181-5. PubMed ID: 11105614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Magnesium and bronchopulmonary dysplasia].
    Fridman E; Linder N
    Harefuah; 2013 Mar; 152(3):158-61, 182. PubMed ID: 23713376
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ventilatory strategies in the prevention and management of bronchopulmonary dysplasia.
    Ambalavanan N; Carlo WA
    Semin Perinatol; 2006 Aug; 30(4):192-9. PubMed ID: 16860159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perinatal conditions related to growth restriction and inflammation are associated with an increased risk of bronchopulmonary dysplasia.
    Eriksson L; Haglund B; Odlind V; Altman M; Ewald U; Kieler H
    Acta Paediatr; 2015 Mar; 104(3):259-63. PubMed ID: 25469645
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bronchopulmonary dysplasia: then and now.
    Philip AG
    Neonatology; 2012; 102(1):1-8. PubMed ID: 22354063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.